Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
7
×
boston top stories
life sciences
national blog main
national top stories
san francisco blog main
fda
national
new york blog main
new york top stories
san francisco top stories
biotech
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
bristol-myers squibb
drug price
jim greenwood
medicare
merck
regeneron pharmaceuticals
abeona therapeutics
affordable care act
agios pharmaceuticals
alirocuma
alzheimer's
ameet nathwani
What
industry
7
×
healthcare
bio
policy
roundup
scalps
american
based
best
biotech
continue
crash
debate
drug
health
kind
life
nash
people
pharmaceutical
politicians
pressure
trump’s
u.s
administration
andreessen
angry
answer
anti
approach
arrival
benefited
biopharma
called
car
celgene
colleagues
companies
days
despite
Language
unset
Current search:
industry
×
" boston blog main "
×
@xconomy.com
3 years ago
Two Days, Six IPOs, and $1B Raised for Biotech Research & More
@xconomy.com
4 years ago
Drug Pricing: Innovation, Investment, and the Public Good
@xconomy.com
5 years ago
Bio Roundup: Trump’s Scalps, Policy Pressure, NASH Crash & More
@xconomy.com
5 years ago
Bio Roundup: Trump’s Scalps, Policy Pressure, NASH Crash & More
@xconomy.com
5 years ago
Losing “Scalps”? Despite Pharma Fear, A Split on Trump Rx-Price Plans
@xconomy.com
5 years ago
Bio Roundup: $74B for Celgene, Two CAR-T Tales, Ready for SF & More
@xconomy.com
5 years ago
Andreessen Leads $300M Bet on Devoted Health’s Senior Care Approach